Erste Asset Management Trims Regeneron Pharmaceuticals Stake

The institutional investor sold 4,661 shares of the biopharmaceutical company in Q3 2025.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Erste Asset Management GmbH, an institutional investor, trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.7% in the third quarter of 2025, according to a recent SEC filing. The firm now owns 48,736 shares of the biopharmaceutical company's stock, valued at $27,329,000 at the end of the reporting period.

Why it matters

Regeneron Pharmaceuticals is a major player in the biopharmaceutical industry, known for its innovative drug discovery technologies. Institutional investors' trading activity in the company's stock can provide insights into market sentiment and potential shifts in the industry.

The details

Erste Asset Management sold 4,661 shares of Regeneron Pharmaceuticals during the third quarter, reducing its total holdings to 48,736 shares. The firm cited portfolio rebalancing as the reason for the share sale. Regeneron's stock price has seen significant volatility in recent quarters, with the share price ranging from $476.49 to $821.11 over the past 12 months.

  • Erste Asset Management filed its Q3 2025 13F report in late February 2026.

The players

Erste Asset Management GmbH

An institutional investor and asset management firm based in Europe.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines.

Got photos? Submit your photos here. ›

The takeaway

Erste Asset Management's decision to trim its Regeneron Pharmaceuticals stake reflects the volatility and uncertainty in the biopharmaceutical sector. Investors will be closely watching how other institutional investors adjust their positions in Regeneron and similar companies in the coming quarters.